General Assembly (GA):

Regulating biotechnology to ensure ethical usage and equitable access

I. Introduction

Biotechnology has become a fundamental component of contemporary science. It has propelled advancements in environmental sustainability, agriculture, and healthcare. Despite the promise it holds, the advantages of biotechnology are not equally shared. Global health and development reports state that millions of people in low- and middle-income nations do not have access to biotechnological innovations that could change their lives. Moreover, the ethical concerns surrounding the misuse of such technologies exacerbate this disparity.

Bridging this inequality, is in line with the Sustainable Development Goals, especially Goal 3 (ensuring healthy lives and promoting well-being for all) and Goal 10 (reducing inequalities). The biggest challenge posed by this issues is developing regulatory frameworks that promote innovation and fair distribution while addressing the moral issues of the technology. To make biotechnology truly accessible to everyone, significant developments in infrastructure and affordability must be ensured.

As we work toward these objectives, it is critical to understand that fair access to biotechnology and ethical regulation encompass issues of global justice rather than just science or policy. If we are able to fully address these issues, we can unlock biotechnology's full potential to improve lives and create a more equitable and sustainable future.

II. Definitions of Key Terms

- *Biotechnology*: the use of biology to develop new products, methods and organisms. The modern practice of biotechnology draws from various disciplines of science and technology, including: molecular biology, chemistry, bionics, genetic engineering, genomics, nanotechnology, informatics, and more. (Barney).

- *Ethical Usage*: the act of using something or the fact of being used in a manner that is morally right or morally acceptable (Pressley and McCormick).

- *Equitable Access*: something that is fair and reasonable in a way that gives equal treatment to everyone (Collins Dictionary).

- *Regulatory Framework*: a set of rules, regulations, and laws that govern the operations and conduct of a particular industry or sector (Dataguard).

- *Intellectual Property Rights (IPRs)*: the rights given to persons over the creations of their minds. They usually give the creator an exclusive right over the use of his/her creation for a certain period of time (WTO).

- *Bioethics*: the study of ethical, social, and legal issues that arise in biomedicine and biomedical research (NIH).

- Genetically Modified Organisms (GMO's): organisms whose genome has been engineered in the laboratory in order to favour the expression of desired physiological traits or the generation of desired biological products (Britannica).

III. Background Information

In the field of biotechnology, ensuring ethical usage and equitable access remains a significant challenge, especially in low- and middle-income countries. This lack of access can be attributed to the following factors:

1. *Economic Barriers*

   High costs associated with biotechnological innovations make them unaffordable for many developing countries. Limited financial resources also hinder governments from investing in the infrastructure required to support biotechnology.

2. *Geographical Disparities*

   Remote and rural areas often lack the infrastructure needed to distribute biotechnological products effectively. Poor transportation networks, insufficient storage facilities, and limited access to healthcare services exacerbate these challenges.

3. *Intellectual Property Rights (IPR)*

   Strict patent protections and intellectual property laws often prevent the distribution of biotechnological innovations. Companies that develop these technologies frequently

prioritize profits over accessibility, leaving people unable to access these treatments or technologies.

4. *Regulatory Gaps*

   Many countries lack robust regulatory frameworks to oversee the safe and ethical implementation of biotechnology. Inconsistent policies across nations create challenges for international cooperation and can lead to unethical practices or misuse of technology.

5. *Ethical Concerns*

   The ethical implications of biotechnological advancements, such as genetic editing and cloning, are widely debated. Concerns over genetic privacy, unintended ecological consequences, and more have led to public resistance in some regions. Ultimately, slowing the development and adoption of these technologies.

6. *Technological Gaps*

   Limited access to research facilities, trained personnel, and modern equipment hampers the development and implementation of biotechnology in lower-middle income countries. These gaps prevent scientists and policymakers from addressing region-specific challenges effectively.

7. *Population Growth and Demand*

   Rapid population growth in developing countries increases the demand for biotechnological solutions. Hence, existing systems are often unprepared to handle this growing need, leading to unequal distribution and strained resources.

IV. Treaties/Historical Events

The Universal Declaration on the Human Genome and Human Rights (1997)

Adopted by UNESCO, this declaration recognizes the human genome as the "heritage of humanity" and calls for ethical principles to guide genetic research. It prohibits genetic discrimination and emphasizes the need to ensure that scientific advancements benefit all people, regardless of socioeconomic status (OHCHR).

The Human Genome Project (1990-2003)

This international scientific endeavor to map the human genome marked a turning point in biotechnology. While it accelerated advancements in genetic research, it also highlighted ethical concerns related to genetic privacy, discrimination, and equitable access to genomic medicine (NHGRI).

The CRISPR Revolution (2012-present)

The development of CRISPR-Cas9 gene-editing technology has sparked significant ethical and regulatory debates. The potential to cure genetic diseases and modify organisms has prompted calls for international agreements to govern its application responsibly.

TRIPS Agreement (1995)

The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), administered by the World Trade Organization (WTO), establishes global standards for intellectual property protection, including biotechnology. However, it has faced criticism for creating barriers to access in low-income countries due to rigid patent protections (WTO).

V. Agencies Involved

World Health Organization (WHO)

The WHO plays a vital role in ensuring the safe and equitable use of biotechnology to improve global health. It provides guidelines and frameworks for the development and distribution of biotechnological advancements like vaccines and gene therapies.

World Trade Organization (WTO)

The WTO oversees intellectual property rights related to biotechnology under the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement. Balances the need to protect innovation with ensuring affordable access to biotechnology in developing countries.

United National Educational, Scientific, and Cultural Organization (UNESCO)

UNESCO focuses on the ethics of biotechnology, advocating for equitable access and respect for human rights in biotechnological applications. One of their key contributions has been the Universal Declaration on the Human Genome and Human Rights.

UNDP

The UNDP integrates biotechnology into its sustainable development efforts, focusing on poverty alleviation, health, and environmental sustainability. It also supports capacity building for biotechnology in developing countries.

VI. Possible Solutions

Strengthening Regulatory Frameworks

Revisit current treaties and develop globally recognized guidelines and safety protocols for biotechnology. It is vital that these guidelines are applied with consistency across borders and that developing nations are supported in establishing and enforcing it through technical expertise, funding, and training.

Reducing Economic Barriers

Offer subsidies or low-interest loans to low-income countries to help them acquire and implement biotechnological solutions. Also, encourage biotechnology companies to adopt tiered pricing strategies, making essential products like vaccines and medicines affordable for poorer nations. This could be supplemented by establishing partnerships between governments, non-profits, and private biotech firms to share costs and risks associated with developing and distributing biotechnological innovations.

Intellectual Property Changes

Promote open-access databases and platforms for sharing research and innovations to foster collaboration between stakeholders and reduce costs. This could be coupled with a change of intellectual property laws regarding biotechnology, allowing for compulsory licensing. Compulsory licensing would enable the production of affordable alternatives to high-cost patented products, reducing financial strain on individuals and healthcare systems. The threat or implementation of compulsory licensing can pressure patent holders to lower prices or offer voluntary licenses.

VII. Works Cited

Australian Government. “The Nagoya Protocol - Convention on Biological Diversity.” *DCCEEW*, 3 January 2025, https://www.dcceew.gov.au/science-research/australias-biological-resources/nagoya-protocol-convention-biological. Accessed 12 January 2025.

Barney, Nick. “What is Biotechnology? Definition, Types and Applications.” *TechTarget*, https://www.techtarget.com/whatis/definition/biotechnology. Accessed 11 January 2025.

Brittanica. “Genetically modified organism (GMO) | Definition, Examples, & Facts.” *Britannica*, 9 January 2025, https://www.britannica.com/science/genetically-modified-organism. Accessed 12 January 2025.

Collins Dictionary. “EQUITABLE ACCESS TO definition and meaning | Collins English Dictionary.” *Collins Dictionary*, https://www.collinsdictionary.com/dictionary/english/equitable-access-to. Accessed 11 January 2025.

Dataguard. “What is a regulatory framework?” *DataGuard*, 14 June 2024, https://www.dataguard.co.uk/blog/what-is-a-regulatory-framework/. Accessed 12 January 2025.

NHGRI. “The Human Genome Project.” *National Human Genome Research Institute*, 18 November 2024, https://www.genome.gov/human-genome-project. Accessed 12 January 2025.

NIH. “Bioethics.” *National Institute of Environmental Health Sciences*, https://www.niehs.nih.gov/research/resources/bioethics. Accessed 11 January 2025.

OHCHR. “Universal Declaration on the Human Genome and Human Rights.” *General Conference of the United Nations Educational, Scientific and Cultural Organization at its twenty-ninth session Share*, https://www.ohchr.org/en/instruments-mechanisms/instruments/universal-declaration-human-genome-and-human-rights. Accessed 12 1 2025.

Pressley, Michael, and Christine McCormick. “ETHICAL definition and meaning | Collins English Dictionary.” *Collins Dictionary*, https://www.collinsdictionary.com/dictionary/english/ethical. Accessed 11 January 2025.

WTO. “Agreement on Trade-Related Aspects of Intellectual Property Rights (unamended).” *WTO Documents*, 15 April 1994, https://www.wto.org/english/docs_e/legal_e/27-trips_01_e.htm. Accessed 12 January 2025.

WTO. “intellectual property (TRIPS) - what are intellectual property rights?” *World Trade Organization*, https://www.wto.org/english/tratop_e/trips_e/intel1_e.htm. Accessed 11 January 2025.